EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer

Tamasine Khadrouche, Mathilde Morisseau, Gabrielle Selmes iD, Charlotte Vaysse, Camille Franchet iD, Carole Massabeau, Mony Ung, Eleonora De Maio iD, Jean-Louis Lacaze iD, Eva Jouve iD

The Breast Journal · 2026-01 · 2026 (1)

DOI: 10.1155/tbj/5534220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 17.07.2026. Verfasst von Tamasine Khadrouche und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Triple Negative Breast Neoplasms, Immunotherapy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II‐III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemotherapy (NAC).

Methods

A retrospective cohort study included 117 Stage II‐III TNBC patients treated with NAIC or NAC (October 2019–May 2023). Surgical complications, time to surgery, time to radiotherapy, and pathologic response were assessed. Complications were classified using the Clavien–Dindo scale; immune‐related adverse events (irAEs) followed the 2017 CTCAE criteria.

Results

Among 117 patients, 59 received NAIC and 58 NAC. Chemotherapy‐related adverse events were similar (NAIC: 78.0%, NAC: 75.9%). irAEs occurred in 50.8% of NAIC patients, with 8.5% experiencing severe irAEs. Surgical complications were more frequent in NAIC (27.1%) than NAC (17.2%), though not statistically significant; seroma was the most common. Delays > 12 weeks in initiating radiotherapy were more frequent in NAIC (10.7%) than NAC (0%).

Conclusion

NAIC did not significantly increase postoperative complications compared to NAC. However, irAEs and potential treatment delays warrant careful management. Despite these risks, NAIC remains a viable option for early TNBC with manageable surgical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyTriple Negative Breast NeoplasmsImmunotherapyHumansFemaleRetrospective StudiesMiddle AgedAgedAdultAntibodies, Monoclonal, HumanizedPathologic Complete ResponseAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomePostoperative Complications

Stichwörter der Autor:innen

immune-related adverse eventsneoadjuvant chemotherapyneoadjuvant immunochemotherapysurgical outcomestriple-negative breast cancer

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Surgical Oncology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
  • Biostatistics & Health Data Science Unit, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
  • Department of Surgical Oncology, University Hospital Center Toulouse-IUCT Oncopole, Toulouse, France.
  • Department of Pathology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
  • Department of Radiotherapy, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
  • Department of Medical Oncology, Claudius Regaud Institute - IUCT Oncopole, Toulouse, France.

ORCID-Profile: Gabrielle Selmes, Camille Franchet, Eleonora De Maio, Jean-Louis Lacaze, Eva Jouve

Zitieren

APA

Khadrouche, T., Morisseau, M., Selmes, G., Vaysse, C., Franchet, C., Massabeau, C., Ung, M., Maio, E., Lacaze, J. L., & Jouve, E. (2026). Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/5534220

Vancouver

Khadrouche T, Morisseau M, Selmes G, Vaysse C, Franchet C, Massabeau C, et al. Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/5534220

BibTeX
@article{Khadrouche2026,
  author = {Khadrouche, Tamasine and Morisseau, Mathilde and Selmes, Gabrielle and Vaysse, Charlotte and Franchet, Camille and Massabeau, Carole and Ung, Mony and Maio, Eleonora De and Lacaze, Jean-Louis and Jouve, Eva},
  title = {Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer},
  journal = {The Breast Journal},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/tbj/5534220}
}
Kostenlos starten →